Off-labelgebruik rituximab bij de ziekte van Castleman

Translated title of the contribution: Off-label rituximab for Castleman's disease

N. Al-Rubaiee, W. Terpstra, M. Crul*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Multicentric Castleman's disease is a lymphoproliferative disorder with a very poor prognosis. Treatment with corticosteroids and different chemotherapeutics has been described, but as yet, no randomized clinical trials have been performed and there is no consensus on the therapy of choice for this disease. A recent publication describes a series of 24 patients who were treated with rituximab with impressive clinical outcome. Based on these findings, we treated a HIV-positive 58 year old male who presented with Castleman's disease with four weekly rituximab infusions in October 2007. He reached a complete remission and tolerated the therapy very well. He has remained symptom-free until the present.

Original languageDutch
Pages (from-to)163-164
Number of pages2
JournalPharmaceutisch Weekblad
Volume144
Issue number38
Publication statusPublished - 18 Sep 2009

Cite this